CLEC4C and CD4+/CD56+ hematodermic neoplasm: In addition to CD56 expression, other aberrancies revealed by flow cytometry in most BPDCN cases include CD7 expression, decreased CD123 expression, decreased or absent CD38 expression, absent CD2 expression, and CD303 expression [37].